Know the Latest MASH Treatment Options
April 2026
The latest indication for injectable semaglutide (Wegovy) will increase focus on metabolic dysfunction-associated steatohepatitis (MASH).
About 15 million adults in the US have MASH...and it’s on the rise.
It’s when fat builds up in the liver, causing inflammation and liver damage. It’s usually asymptomatic, and if left untreated, it can progress to fibrosis, cirrhosis, liver failure, or death.
Get concise advice on drug therapy, plus unlimited access to CE
Pharmacist's Letter membership benefits include:
- 12 issues every year — what you need to know and do, right now
- Quick, practical reference charts and tools
- Comprehensive CE library to meet license renewal and state requirements
- Multiple course formats including live webinars, podcasts, and CE-in-the-Letter to match your learning style
- Plus much more!
Choose the right tier for your needs today.
Already a subscriber? Log in
Volume pricing available. Get a quote